Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Francoise Redini"'
Autor:
Maria Eugénia Marques Da Costa, Sakina Zaidi, Jean-Yves Scoazec, Robin Droit, Wan Ching Lim, Antonin Marchais, Jerome Salmon, Sarah Cherkaoui, Raphael J. Morscher, Anouchka Laurent, Sébastien Malinge, Thomas Mercher, Séverine Tabone-Eglinger, Isabelle Goddard, Francoise Pflumio, Julien Calvo, Francoise Redini, Natacha Entz-Werlé, Aroa Soriano, Alberto Villanueva, Stefano Cairo, Pascal Chastagner, Massimo Moro, Cormac Owens, Michela Casanova, Raquel Hladun-Alvaro, Pablo Berlanga, Estelle Daudigeos-Dubus, Philippe Dessen, Laurence Zitvogel, Ludovic Lacroix, Gaelle Pierron, Olivier Delattre, Gudrun Schleiermacher, Didier Surdez, Birgit Geoerger
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-15 (2023)
Abstract Pediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial (NCT02613962). To date, 1
Externí odkaz:
https://doaj.org/article/0bccef955fcd4460a5c66a0d211aaac0
Publikováno v:
Cells, Vol 9, Iss 4, p 976 (2020)
Osteosarcomas are the most frequent primary bone sarcomas, affecting mainly children, adolescents, and young adults, and with a second peak of incidence in elderly individuals. The current therapeutic management, a combined regimen of poly-chemothera
Externí odkaz:
https://doaj.org/article/5e29aa368b1f4dc89a1dd7e3f7abc70e
Autor:
Francois Lamoureux, Francoise Redini, Dominique Heymann, Séverine Battaglia, Jérôme Amiaud, Thibaut Quillard, Bénédicte Brounais-Le Royer, Franck Verrecchia, Marc Baud'huin, Benjamin Ory
Primer and antibodies table
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a9594d298e0991992c8face43674a53
https://doi.org/10.1158/1078-0432.22459097.v1
https://doi.org/10.1158/1078-0432.22459097.v1
Autor:
Francois Lamoureux, Francoise Redini, Dominique Heymann, Séverine Battaglia, Jérôme Amiaud, Thibaut Quillard, Bénédicte Brounais-Le Royer, Franck Verrecchia, Marc Baud'huin, Benjamin Ory
supplemental figure legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1087504adea8a619978f5354372a31f3
https://doi.org/10.1158/1078-0432.22459094
https://doi.org/10.1158/1078-0432.22459094
Autor:
Francois Lamoureux, Francoise Redini, Dominique Heymann, Séverine Battaglia, Jérôme Amiaud, Thibaut Quillard, Bénédicte Brounais-Le Royer, Franck Verrecchia, Marc Baud'huin, Benjamin Ory
Supp. Figure 2. HSP90 inhibition induces client proteins degradation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b98b97a3293fed098693db9b444d8ca
https://doi.org/10.1158/1078-0432.22459103.v1
https://doi.org/10.1158/1078-0432.22459103.v1
Autor:
Francois Lamoureux, Francoise Redini, Dominique Heymann, Séverine Battaglia, Jérôme Amiaud, Thibaut Quillard, Bénédicte Brounais-Le Royer, Franck Verrecchia, Marc Baud'huin, Benjamin Ory
Purpose: Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants the development of new strategies to improve overall patient survival. Among them, HSP90 is a molecu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3a3adda3149ce84040ad3186f14658
https://doi.org/10.1158/1078-0432.c.6524129.v1
https://doi.org/10.1158/1078-0432.c.6524129.v1
Autor:
Francois Lamoureux, Francoise Redini, Dominique Heymann, Séverine Battaglia, Jérôme Amiaud, Thibaut Quillard, Bénédicte Brounais-Le Royer, Franck Verrecchia, Marc Baud'huin, Benjamin Ory
Supp. Figure 1. HSP90 messenger RNA level is overexpressd in osteosarcoma patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3921b64070c913312551ec24dcecef0
https://doi.org/10.1158/1078-0432.22459106
https://doi.org/10.1158/1078-0432.22459106
Autor:
Maryne Dupuy, Maxime Gueguinou, Mathilde Mullard, Robel Tesfaye, Jerome Amiaud, Sarah Morice, Benjamin Ory, Francoise Redini, Christophe Vandier, Franck Verrecchia
Publikováno v:
Cancer Research. 82:6267-6267
Ewing sarcoma (ES) is the second most common primary bone tumor among children and teenagers. The survival rate for patients is about 70%, but drops dramatically to less than 30% when metastases are present at diagnostic. The current treatment consis
Autor:
Maryne Dupuy, François Lamoureux, Mathilde Mullard, Anaïs Postec, Laura Regnier, Marc Baud’huin, Steven Georges, Bénédicte Brounais-Le Royer, Benjamin Ory, Françoise Rédini, Franck Verrecchia
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
In Europe, with an incidence of 7.5 cases per million, Ewing sarcoma (ES) is the second most common primary malignant bone tumor in children, adolescents and young adults, after osteosarcoma. Since the 1980s, conventional treatment has been based on
Externí odkaz:
https://doaj.org/article/96f03fca6f38466183cb1831951cf9a6
Autor:
Clément Veys, Flavie Boulouard, Abderrahim Benmoussa, Manon Jammes, Emilie Brotin, Françoise Rédini, Laurent Poulain, Nicolas Gruchy, Christophe Denoyelle, Florence Legendre, Philippe Galera
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Chondrosarcomas and osteosarcomas are malignant bone tumors with a poor prognosis when unresectable or metastasized. Moreover, radiotherapy and chemotherapy could be ineffective. MiRNAs represent an alternative therapeutic approach. Based on high-thr
Externí odkaz:
https://doaj.org/article/ca6a80213c7749da80be7ec384cce913